Silicon Valley Bank’s Healthcare Investments & Exits report

By Helen Adams
SVB's annual Healthcare Investments and Exits report is out, key features include data on healthtech, venture fundraising and SVB's 2022 outlook

Since 1983, Silicon Valley Bank (SVB) has supported innovators and their investors taking their ideas onward. The company is also a leader in healthcare funding, healthcare banking and life science banking. 

SVB has released its annual Healthcare Investments and Exits report, which features global analysis on how healthcare funding and investments, as well as VC-backed exits, have helped SVB make records in 2021. 

Here is a summary of the key points:

 

Biopharma seed

Biopharma investment set a new record with US$6.8bn financings (twice the amount from 2020), yet remained flat in Europe.

Biopharma saw increased funding in platform, neurology and anti-infective while orphan/rare activity continued to slow. 

 

Dx/Tools seed

The UK has continued to be a popular spot for Dx investment deals, with 20 seed/series A deals.

Elsewhere, Dx/tool investment saw a new record with the number of US$100mn+ financings that grew three times as large from 2020, to 40 in the US/EU.

 

Exits

While the venture backed healthcare industry saw record IPO activity across the board the average post-IPO performance for 2021 was muted (-21% average).

Although SPAC mergers were also up this year, it was a poor year for de-SPAC performance (- 44% average).

 

Healthtech

Healthtech experienced the greatest increase in investment of 162%. 

The device market saw a 4x increase in European investment specifically, while Healthtech also saw the number of financials with US$1bn+ valuations explode and the creation of 42 new unicorns.

 

Venture Fundraising

New venture funds allocated to healthcare in 2021 nearly doubled 2020’s record, with investment into companies exceeding US$86bn in the US & EU (30% increase from 2020) leading every sector to hit record highs.

 

Silicon Valley Bank’s 2022 outlook

In EU and US companies, venture healthcare investment is due to total about US$64bn, as Venture Capitalists decrease their deal pace, while continuing to invest from recently closed funds.

 

Share

Featured Articles

World Hepatitis Summit 2022 to support healthcare workers

The World Hepatitis Summit 2022 calls to prevent viral hepatitis as cases soar in children and healthcare workers struggle with the stigma

5 minutes with Yoni Nevo, CEO of Sweetch

At behavioural science company Sweetch, CEO Yoni Nevo treats chronic illnesses with digital therapeutics solutions, using AI & emotional intelligence

Canada’s telehealth support for Ukrainian healthcare workers

McGill University has stepped up to support healthcare workers in Ukraine with training videos to help provide life-saving care for those in the conflict

How Contura’s hydrogel technology can help patients knees

Technology & AI

MVP Health Care’s Kim Kilby on hybrid healthcare’s future

Hospitals

Loylogic’s path leads to higher healthcare app engagement

Digital Healthcare